MR imaging of HER-2 in CNS tumors using Affibody
Project/Area Number |
21791359
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
Cerebral neurosurgery
|
Research Institution | Osaka University |
Principal Investigator |
KINOSHITA Manabu Osaka University, 医学系研究科, 助教 (40448064)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 分子イメージング / MRI / Affibody / SPIO / HER-2 |
Research Abstract |
Detecting HER-2 expression is clinically relevant, as treatment methods and prognosis differ according to HER-2 expression status. In this study, we have focused on a small molecule named Affibody, which is one-tenth in molecular size of an antibody, possessing equal capability. SPIO was labeled to Affbody for MRI detection. When HER-2 overexpressing tumor (SKOV-3 ovarian cancer cell line) was inoculated to a SCID mouse, Affibody-SPIO successfully imaged HER-2 receptor on MRI. Accumulation of Affibody and SPIO was confirmed on histology.
|
Report
(3 results)
Research Products
(51 results)
-
-
-
-
-
[Journal Article] Effects of concomitant temozolomide and radiation therapies on WT1-specific T cells in malignant glioma.2010
Author(s)
Chiba Y, Hashimoto N, Tsuboi A, Oka Y, Maruo A, Kinoshita M, Kagawa N, Oji Y, Hosen N, Nishida S, Sugiyama H, Yoshimine T.
-
Journal Title
Jpn J Clin Oncol. 40(5)
Pages: 395-403
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] A survey of disclosure of diagnosis to patients with glioma in Japan.
Author(s)
Yamamoto F, Hashimoto N, Kagawa N, Okita Y, Chiba Y, Kijima N, Kinoshita M, Yoshizu K, Fujimoto Y, Hirai K, Yoshimine T.
-
Journal Title
Int J Clin Oncol. in press
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-